U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109297) titled 'Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India' on July 31.
Brief Summary: The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
RSV Immunization
Intervention:
BIOLOGICAL: Nir...